Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Lung Neoplasms ALK gene crizotinib
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 347
Healthy volunteers: no

Brief summary:
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Detailed description:

Arms:
arm 1: None arm 2: Investigator selection of either pemetrexed or docetaxel as the active comparator

Interventions: intervention 1: PF-02341066 intervention 2: Pemetrexed intervention 3: Docetaxel
Intervention descriptions: intervention 1: PF-02341066, 250 mg BID will be administered orally on a continuous schedule intervention 2: Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle intervention 3: Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle

Protocol document: